> **Introduction and gene overview**
>
> Human **GTPBP2** encodes **GTP-binding protein 2** (UniProt **Q9BX10**), a member of the **translational GTPase** family related to factors that regulate elongation and ribosome rescue. Recent human genetics and translation-focused reviews consistently identify GTPBP2 as a factor involved in **ribosomal homeostasis**, **mRNA translation quality control**, and **neuronal proteostasis**, matching the supplied UniProt assignment for the human protein rather than another gene/protein with a similar name (pqac-00000000, pqac-00000001, pqac-00000015). GTPBP2 is closely related to GTPBP1; the two proteins share substantial sequence similarity and are discussed together in the current literature as homologous translational GTPases with overlapping roles in ribosome-associated quality control and nervous-system maintenance (pqac-00000000). Recent work in humans established that bi-allelic loss-of-function variants in **GTPBP2** cause a recognizable neurodevelopmental disorder, further confirming that the human protein has a conserved and clinically important role in translational homeostasis (pqac-00000000).
>
> **Primary molecular function**
>
> The best-supported current model is that GTPBP2 acts primarily as a **ribosome rescue factor** during **translation elongation**. Foundational mouse work showed that GTPBP2 deficiency causes **prolonged ribosome pausing at AGA arginine codons** when the cognate **tRNA\_Arg(UCU)** pool is limiting, strongly indicating that GTPBP2 resolves elongation complexes stalled by codon-specific decoding problems rather than functioning as a canonical metabolic enzyme with a small-molecule substrate (pqac-00000002, pqac-00000004, pqac-00000011). Reviews published in 2021–2025 describe GTPBP2 as a mammalian **ribosome rescue factor** that helps clear aberrantly stalled ribosomes and thereby limits accumulation of defective nascent chains and translational stress (pqac-00000003, pqac-00000005, pqac-00000007, pqac-00000014, pqac-00000015, pqac-00000017).
>
> GTPBP2 is a **GTPase**, but direct biochemical detail for human GTPBP2 remains limited compared with canonical elongation factors; accordingly, the strongest claim supported by the available literature is that **GTP hydrolysis is coupled to ribosome rescue/recycling events** rather than to a classical biosynthetic reaction. Its relevant “substrate specificity” is therefore best understood at the level of **stalled ribosomal complexes**, especially those paused during elongation when decoding is impaired. The clearest experimentally demonstrated case is pausing at **AGA codons** under conditions of limited cognate tRNA availability, although review articles place GTPBP2 more broadly in the machinery that responds to translational stalls caused by aberrant mRNAs or problematic elongation states (pqac-00000002, pqac-00000004, pqac-00000011, pqac-00000017).
>
> **Subcellular localization**
>
> Available evidence supports a primarily **ribosome-associated cytoplasmic function** for GTPBP2, because the key mechanistic and disease-linked studies concern stalled **80S cytosolic ribosomes** during translation elongation in neurons and other cells (pqac-00000002, pqac-00000004, pqac-00000014, pqac-00000017). Reviews of ribosome rescue and RQC also situate GTPBP2 within the eukaryotic cytosolic surveillance machinery that detects and resolves problematic translating ribosomes (pqac-00000003, pqac-00000005, pqac-00000007).
>
> Some review literature discusses GTPBP2 in the broader context of mitochondrial proteostasis or mitochondrial-associated translation stress, but the strongest direct evidence in the retrieved sources supports **cytosolic translation quality control** rather than a definitively established autonomous mitochondrial localization for human GTPBP2 itself (pqac-00000008, pqac-00000013, pqac-00000015). Therefore, the most evidence-based localization statement is that GTPBP2 acts **on ribosomes in the cytoplasm**, with disease consequences that intersect with mitochondrial and neuronal homeostasis indirectly through proteostasis failure and stress signaling (pqac-00000002, pqac-00000004, pqac-00000015).
>
> **Biological processes and signaling pathways**
>
> GTPBP2 participates in **ribosome-associated quality control (RQC)** and closely related ribosome rescue pathways that maintain translational fidelity and proteostasis. Reviews describe collided or stalled ribosomes as central triggers for surveillance pathways that split ribosomes, degrade aberrant mRNAs, and dispose of incomplete nascent chains; GTPBP2 is repeatedly cited as one of the mammalian rescue factors acting upstream of or alongside these pathways (pqac-00000003, pqac-00000005, pqac-00000007, pqac-00000014, pqac-00000015, pqac-00000017).
>
> GTPBP2 deficiency also links elongation defects to the **integrated stress response (ISR)**. In the mouse Gtpbp2 model, unresolved stalling caused increased **eIF2α phosphorylation** and activation of **ATF4** target genes via **GCN2**, demonstrating that ribosome pausing can signal from elongation to initiation control. Importantly, this ISR response was observed before overt neurodegeneration and appeared to be at least partly protective in that model (pqac-00000004, pqac-00000011). A later study of the homologous GTPBP1 pathway likewise found GCN2-dependent ISR activation and reduced **mTORC1** signaling during tRNA deficiency and ribosome pausing, reinforcing the idea that GTPBP-family rescue factors sit at the interface of translation elongation control, neuronal homeostasis, and stress signaling (pqac-00000002).
>
> GTPBP2 is also discussed in relation to **no-go decay (NGD)** and broader mRNA surveillance. While the retrieved texts emphasize RQC more directly than NGD, reviews of stalled-ribosome surveillance place ribosome rescue factors such as GTPBP2 in the network that couples translational arrest to **mRNA decay**, **ribosome splitting**, and **nascent-chain quality control** (pqac-00000016, pqac-00000017). In neurons, these functions are especially important because codon-specific decoding stress and unresolved pauses can trigger selective vulnerability and cell death (pqac-00000002, pqac-00000010, pqac-00000014).
>
> **Molecular mechanism and cooperation with PELO/HBS1L**
>
> Mechanistically, GTPBP2 is most often discussed as cooperating with the conserved ribosome rescue factors **PELO** (Pelota) and **HBS1L**. Reviews of mammalian ribosome rescue describe **PELO–HBS1L** as the core machinery that recognizes stalled ribosomes and recruits **ABCE1** to promote subunit dissociation; GTPBP2 is placed in this rescue framework as a mammalian factor required for efficient resolution of specific stalled elongation complexes, particularly internally stalled ribosomes caused by defective decoding (pqac-00000006, pqac-00000014, pqac-00000017). Additional reviews explicitly note that GTPBP2 has been linked to the response to ribosome stalling caused by tRNA deficiency and discuss it together with HBS1L/PELO-type rescue mechanisms upstream of downstream RQC events (pqac-00000005, pqac-00000007).
>
> Thus, the most conservative mechanistic synthesis is that GTPBP2 is a **translational GTPase acting on stalled 80S ribosomes**, functionally allied with **PELO/HBS1L/ABCE1-mediated rescue**, to enable **ribosome splitting/recycling** and prevent persistence of elongation-blocked complexes. The resulting release of stalled ribosomes protects cells from secondary collision-driven proteotoxicity and stress signaling (pqac-00000003, pqac-00000006, pqac-00000014, pqac-00000017).
>
> **Clinical significance**
>
> Human disease evidence for GTPBP2 has strengthened substantially. Earlier reports linked rare **GTPBP2** variants to severe neurological disease, including neurodevelopmental and neurodegenerative phenotypes; more recent work consolidated these observations into a clearer syndrome concept (pqac-00000002, pqac-00000004, pqac-00000013). In the largest recent study, **20 individuals from 16 families** with bi-allelic variants in **GTPBP1 or GTPBP2** were described, and the shared syndrome included **microcephaly, profound neurodevelopmental impairment, characteristic craniofacial features, ectodermal defects, abnormal vision and/or hearing, progressive spasticity, choreoathetoid movements, refractory epilepsy, and brain atrophy** (pqac-00000000). Functional studies in patient fibroblasts supported a **loss-of-function** mechanism, and reduced expression of the fly ortholog produced locomotor impairment, consistent with evolutionary conservation of the pathway (pqac-00000000).
>
> Expert reviews interpret these findings within a broader framework in which failure of ribosome rescue/RQC preferentially harms neurons because of their dependence on long-lived proteostasis, precise translational control, and sensitivity to codon-tRNA imbalances. This interpretation is strongly supported by the tRNA-dysregulation literature, which highlights GTPBP2 as one of the key rescue factors whose loss converts altered tRNA supply into overt neurodegeneration (pqac-00000010, pqac-00000014, pqac-00000015).
>
> **Recent developments and current understanding (2023–2024 emphasis)**
>
> The most important recent advance is the 2024 human genetics study establishing that bi-allelic variants in **GTPBP2** and its homolog **GTPBP1** cause an **identical, distinct neurodevelopmental syndrome**, substantially refining the phenotype and moving GTPBP2 from a candidate neurological gene to a well-supported Mendelian disease gene (pqac-00000000). A 2023 survey of human translation machinery also highlighted GTPBP2 among translation-related factors relevant to tissue specialization, reinforcing the view that it belongs functionally within the translation-control apparatus rather than in unrelated signaling categories (pqac-00000001).
>
> The 2023 review literature further sharpened the mechanistic context by emphasizing how deficits in tRNA biology, codon demand/supply imbalance, and stalled-ribosome surveillance converge in neurodevelopmental disease. In that framework, GTPBP2 is not merely an accessory factor but a critical **failsafe for elongation stress**, especially in neurons (pqac-00000010, pqac-00000016). Overall, the present consensus is that human GTPBP2 is a **ribosome-associated translational GTPase whose primary job is to rescue stalled elongating ribosomes, limit proteotoxic translation products, and connect elongation surveillance to cell-wide stress adaptation and neuronal survival** (pqac-00000000, pqac-00000003, pqac-00000004, pqac-00000015).
>
> **Bottom line**
>
> Taken together, the available evidence supports a focused functional annotation for human GTPBP2: it is a **cytosolic ribosome rescue GTPase** acting in **translation elongation quality control**, with strongest evidence for resolving **codon-specific ribosome pausing at AGA codons under limiting tRNA conditions**; it functions in the broader **RQC/NGD/ISR network**, likely in concert with **PELO/HBS1L/ABCE1**, and its loss causes severe **human neurodevelopmental disease** because neurons are exceptionally vulnerable to unresolved translational stress (pqac-00000000, pqac-00000002, pqac-00000004, pqac-00000014, pqac-00000015, pqac-00000017).


*Blockquote: This blockquoted artifact provides a citation-supported scientific report on human GTPBP2, summarizing its identity, molecular function in ribosome rescue, pathway context, localization, and disease relevance. It is useful as a compact evidence-backed narrative for final functional annotation.*